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Abstract
Background: Delirium is a common disorder in the early phase of stroke. Given the presumed
cholinergic deficiency in delirium, we tested treatment with the acetylcholinesterase inhibitor
rivastigmine.
Methods: This pilot study was performed within an epidemiological study. In 527 consecutive
stroke patients presence of delirium was assessed during the first week with the confusion
assessment method. Severity was scored with the delirium rating scale (DRS). Sixty-two patients
developed a delirium in the acute phase of stroke. Only patients with a severe and persistent
delirium (defined as a DRS of 12 or more for more than 24 hours) were enrolled in the present
study. In total 26 fulfilled these criteria of whom 17 were treated with orally administered
rivastigmine with a total dose between 3 and 12 mg a day. Eight patients could not be treated
because of dysphagia and one because of early discharge.
Results: No major side effects were recorded. In 16 patients there was a considerable decrease
in severity of delirium. The mean DRS declined from 14.8 on day one to 8.5 after therapy and 5.6
after tapering. The mean duration of delirium was 6.7 days (range; 2–17).
Conclusion: Rivastigmine is safe in stroke patients with delirium even after rapid titration. In the
majority of patients the delirium improved after treatment. A randomized controlled trial is needed
to establish the usefulness of rivastigmine in delirium after stroke.
Trial registration: Nederlands Trial Register NTR1395
Background
Delirium is a frequent complication of stroke and some-
times the presenting feature. Estimates of the incidence of
delirium in the early phase of stroke range from 13 to 48%
dependent on study population and delirium definition.
[1-6] Given the longer hospitalization period and poorer
prognosis, adequate treatment is important[3,4]. Sedative
and anti-psychotic drugs are frequently used, but the
effect of these drugs in stroke patients is often disappoint-
ing and severe side effects are reported[7].
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Decreased cholinergic activity,[8,9] decreased cholinergic
reserve, and decreased acetylcholine in the basal nucleus
of Meynert [10] are postulated as neurochemical corre-
lates of delirium. Furthermore, drugs with anticholinergic
effects may induce delirium,[11] and cholinergic drugs
can improve delirium induced by lithium and anticholin-
ergic medication.[12,13] Therefore, treating the choliner-
gic deficiency in delirium patients might be beneficial.
Acetylcholinesterase inhibitors have been used success-
fully in the treatment of patients with Alzheimer's disease
[14] and Lewy body dementia.[15]
To the best of our knowledge cholinergic drugs have not
been studied in patients with delirium in the early phase
post-stroke. In the present study we aimed to assess the
feasibility and safety profile of the acetylcholinesterase
inhibitor rivastigmine in patients with delirium after a
recent stroke. Because of the need for rapid intervention in
delirium we tested a novel titration scheme for rivastig-
mine.
Methods
In a prospective study, 527 consecutive stroke patients
were screened for the presence of delirium by means of
the Confusion Assessment Method (CAM) during the first
week of admission[16]. If positive, the severity was meas-
ured daily with the Delirium Rating Scale (DRS)[17].
Screening for delirium was performed twice, on day 2–4
and day 5–7. In case of delirium the DRS was repeated
daily. Patients with a severe and persistent delirium,
defined as a DRS above 12 for more than 24 hours,[17]
were included in the current pilot study. Sufficient effect
of treatment was defined as a DRS of 10 or less. Pre-exist-
ing cognitive decline was measured by means of the
Informant Questionnaire on Cognitive Decline in the Eld-
erly (IQCODE).[18,19] Stroke subtype and severity were
scored with the Oxfordshire Community Stroke Project
(OCSP) criteria [20,21] and the National Institutes of
Health Stroke Scale (NIHSS).[22].
Rivastigmine was started in a dose of 1.5 mg b.i.d., and
was raised every other day by 3 mg, depending on the clin-
ical response, with a maximum of 12 mg a day (i.e. day 1:
1.5 mg b.i.d., day 3: 3 mg b.i.d., day 5: 4.5 mg b.i.d., day
7: 6 mg b.i.d.). If the DRS remained below 10 the rivastig-
mine dosage was continued for one week and subse-
quently tapered at a rate similar to the titration scheme.
The study protocol was reviewed and approved by the
medical ethics committee of the St Elisabeth Hospital
Tilburg (ref 0307) and subsequently approved in a short
procedure by the medical ethics committee of the TweeSt-
eden Hospital Tilburg. This study was carried out in com-
pliance with the Helsinki Declaration. Informed consent
was obtained from the caregivers.
Results
In the prospective study 62 patients (11.6%) had a delir-
ium. Thirty-four of these patients had a DRS score below
twelve, and 2 were already treated with antipsychotic
medication. Hence, 26 patients were included in the
present study. Since at time of the study rivastigmine
could be administered by oral route only, it had to be
interrupted in eight patients with severe dysphagia. In one
patient rivastigmine was stopped because of discharge to
a nursing home. Characteristics and treatment effect of the
17 patients included in the study are summarized in Table
1. The mean age of the treated patients was 77 years, 65%
were men. Right sided hemispheric strokes occurred in
59%. The median NIHSS on admission was 9 (range 2–
32).
Of the 17 patients with delirium, 12 had an infection and
were treated with antibiotics. Seven patients had a meta-
bolic disturbance that could causally be related to the
delirium. Nine patients had a hyperactive/hyperalert type
of delirium, 6 hypoactive/hypoalert, and 2 had a mixed
type. In 16 of the 17 (94%) patients there was a decrease
in severity of delirium following rivastigmine treatment
(Figure 1). The mean DRS decreased from 14.8 at start of
rivastigmine to 8.5 at individual maximum dose and 5.6
after tapering. Four patients needed 3 mg rivastigmine per
day, 5 patients 6 mg, 5 patients 9 mg, and 2 patients
needed 12 mg. The mean duration of the delirium in these
16 patients was 6.7 days (range 2–17). In all patients it
was possible to taper the dose of rivastigmine without
recurrence of delirium in the first month. One patient
showed no response at all, despite a daily rivastigmine
dose of 9 mg (patient 13). This patient was admitted with
an acute confusion that was caused by an intracerebral
hemorrhage. Her medical history reported dementia but
she was never formally analyzed and diagnosed. The
IQCODE of 78 was consistent with dementia. When treat-
ing with rivastigmine there was no effect at all and despite
the fact that she was not at the highest dose we chose to
change her medication to haloperidol. The confusion
only slightly declined but since there was no aggression
no further sedative drugs were started. After 2 weeks she
was admitted to a nursing home and was lost to follow up.
Only 2 patients suffered from diarrhoea (both at high
doses), which in one of them could be caused by a pre-
existing ulcerative colitis. Nausea or cardiac complications
did not occur. Five patients needed additional medication
because of agitation at night and insomnia. These patients
were treated with temazepam in a dose between 10–20
mg. Haloperidol was allowed in the protocol as rescue
medication. Only in one patient (pat 13) this has been
used.BMC Neurology 2008, 8:34 http://www.biomedcentral.com/1471-2377/8/34
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Discussion
We showed that it is possible and safe to treat patients
with severe delirium in the acute phase after stroke with
rivastigmine, and that low doses sufficed in the majority
of the patients. This is in line with the excellent tolerabil-
ity in Lewy body and Parkinson dementia, diseases with a
presumed severe cholinergic deficiency.[15,23]. An
important observation is the possibility to increase the
dose rapidly without serious side effects making rapid
intervention possible. A major drawback in the use of
rivastigmine was the absence of a parenteral route for
administration. In confused patients unable to swallow,
nasogastric feeding is often not tolerated or unsafe.
In the American practice guideline for treatment of delir-
ium, haloperidol is first choice,[24] notwithstanding its
anticholinergic side-effects,[8] a risk factor for delir-
ium.[11] Moreover, haloperidol may interfere with recov-
ery after stroke and therefore should be avoided if
possible.[25] A possible explanation for the effect of
rivastigmine can be an improvement of preexisting
dementia-symptoms in our patient group. However, in
the medical history only 1 patient was reported with
dementia (patient 13). We did not use the minimal men-
tal state examination (MMSE) as an indicator of dementia
because it has been shown to be unreliable in the acute
phase after stroke.[26] Instead we used the IQCODE
which gives an impression of cognitive deterioration in
the past ten years. Using the cut off point of 3.9 per item
[27] only 2 patients were in the range of dementia (patient
3 and 13). Also the fact that we could taper the dose of
rivastigmine without recurrence of the cognitive symp-
toms indicates that we indeed treated the delirium symp-
toms and not the symptoms of undiagnosed dementia.
Case reports have suggested that acetylcholinesterase
inhibitors can be used in the treatment of delirium in
patients with dementia, Parkinson's disease, and elderly
patients with long-standing delirium.[12,13,28] Treat-
ment with rivastigmine has not been described in patients
with delirium in the early phase after stroke. Obviously,
the uncontrolled design and small number of patients do
not allow conclusions with respect to the therapeutic
value in patients with delirium after stroke, but our study
suggests that rivastigmine might be useful in this setting.
Therefore, a randomized controlled trial is needed in
which rivastigmine will be compared with standard treat-
ment. The novel transdermal administration of rivastig-
mine may be indicated in patients with delirium after
stroke because of frequent swallowing problems[29].
Conclusion
Rivastigmine is safe in stroke patients with delirium even
after rapid titration. In the majority of patients the delir-
ium improved after treatment. A randomized controlled
trial is needed to establish the usefulness of rivastigmine
in delirium after stroke.
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Table 1: Patient characteristics and treatment effect of rivastigmine.
Patient 
(gender)
Age (years) IQCODE Stroke 
localization
Stroke type NIHSS Highest daily 
dose (mg)
Effect Delirium 
duration (days)
1(F) 69.2 53 Right PACI 5 6 Yes 4
2(M) 73.9 48 Right TACI 15 9 Yes 6
3(M) 85.0 70 Right POCI 3 3 Yes 3
4(M) 83.4 48 Right POCI 6 9 Yes 11
5(M) 80.7 48 Right PACI 4 6 Yes 3
6(F) 74.1 48 Right PACI 3 3 Yes 2
7(M) 53.4 48 Left PACI 16 12 Yes 14
8(M) 75.0 48 Right TACI 11 12 Yes 17
9(M) 82.5 48 Right POCI 4 3 Yes 2
10(F) 78.2 48 Right PACI 2 9 Yes 11
11(M) 85.5 58 Right LACI 3 3 Yes 2
12(M) 72.9 51 Left TACI 20 6 Yes 5
13(F) 72.8 78 Left ICH 9 9 No 14
14(M) 86.5 48 Left LACI 7 9 Yes 8
15(F) 79.3 48 Left PACI 9 6 Yes 4
16(M) 76.6 48 Left ICH 15 6 Yes 8
17(F) 79.4 48 Left ICH 9 9 Yes 7
F = Female; M = Male. PACI = Partial Anterior Circulation Infarction; TACI = Total Anterior Circulation Infarction; POCI = Posterior Circulation 
Infarction; LACI = Lacunar Infarction; ICH = Intracerebral HemorrhageBMC Neurology 2008, 8:34 http://www.biomedcentral.com/1471-2377/8/34
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